

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10562807
	Filing Date		2006-07-06
	First Named Inventor	David Paul Humphreys	
	Art Unit	1643	
	Examiner Name	David J. Blanchard	
	Attorney Docket Number	07-1047-WO-US	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10562807
Filing Date	2006-07-06
First Named Inventor	David Paul Humphreys
Art Unit	1643
Examiner Name	David J. Blanchard
Attorney Docket Number	07-1047-WO-US

1	HUMPHREYS, David P. et al.: "Co-expression of human protein disulphide isomerase (PDI) can increase the yield of an antibody Fab' fragment expressed in Escherichia coli," FEBS Letters 380 (1996) 194-197.	<input type="checkbox"/>
2	HUMPHREYS, David P. et al.: "Formation of dimeric Fabs in Escherichia coli: effect of hinge size and isotype, presence of interchain disulphide bond, Fab' expression levels, tail piece sequences and growth conditions,," Journal of Immunological Methods 209 (1997) 193-202.	<input type="checkbox"/>
3	KOUMENIS, Iphigenia Leonidou et al.: "Modulating pharmacokinetics of an anti-interleukin-8 F(ab') ₂ by amine-specific PEGylation with preserved bioactivity," International Journal of Pharmaceutics 198 (2000) 83-95.	<input type="checkbox"/>
4	LEONG, Steven R. et al.: "ADAPTING PHARMACOKINETIC PROPERTIES OF A HUMANIZED ANTI-INTERLEUKIN-8 ANTIBODY FOR THERAPETUIC APPLICATIONS USING SITE-SPECIFIC PEGYLATION," CYTOKINE, Vol. 16, No. 3 (7 November), 2001, pages 106-119.	<input type="checkbox"/>
5	WETZEL, Ronald: "Harnessing disulfide bonds using protein engineering," TIBS 12 - December 1987, pages 478-482.	<input type="checkbox"/>
6	KATZ, Bradley A. and KOSSIAKOFF, Anthony: "The Crystallographically Determined Structures of Atypical Strained Disulfides Engineered into Subtilisin," The Journal of Biological Chemistry, Vol. 261, No. 33, Issue of November 25, pages 15480-15485, 1986.	<input type="checkbox"/>
7	MITCHINSON, Colin and WELLS, James A.: "Protein Engineering of Disulfide Bonds in Subtilisin BPN'," Biochemistry 1989, 28, pages 4807-4815.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.